Advanced Code injection
 
 

CAAP® – Building Companies

The OBIO® Capital Access Advisory Program (CAAP®) operates downstream from existing entrepreneurship programs and focuses on accelerating technology commercialization, working towards Series A financing and strategic partnerships. OBIO’s CAAP® creates high value deal flow for both companies and investors, culminating with a presentation at the OBIO® Investment Summit
in 2024.

What is OBIO’s CAAP®?

  • A competitive, 9-month structured program for health science companies starting to raise Series A financing
    in Q4 2023 to 2024 timeframe.

  • CAAP® covers three fundamental business themes:

    • Business strategic planning & increasing the ROI for investors

    • Advanced fundraising strategies & financial modeling

    • Closing an investment round

Benefits for CAAP® companies:

  • Strategic guidance from an international Steering Committee of investors, healthcare executives and business experts on how to position for a successful raise

  • Access to a network of advisors with expertise in technology commercialization, business development, fundraising and negotiations

  • Investor readiness, targeting and introductions

CAAP® culminates with a presentation at the OBIO Investment Summit:

• Present to and meet with global health sciences investors & strategics

• > $1.3B raised by Summit companies since 2018

• 160 companies have presented at the Summit

Have a question? Contact us:

CHRISTINA YEH
Vice President, Technology Commercialization
christinayeh@obio.ca

JACK LEE
Director, Technology Commercialization
jacklee@obio.ca


CAAP® Companies 2023

CAAP® Companies 2022

 
 

CAAP® Companies 2021

 
 

CAAP® Companies 2020

 
 

CAAP® Companies 2019

 
 
Canada logo_2.jpg